Lessons for clinical trials from natalizumab in multiple sclerosis.
Chaudhuri
Abhijit
A
Essex Centre for Neurological Sciences, Oldchurch Hospital, Romford RM7 0BE. chaudhuria@gmail.com
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D002465:Cell Movement / Q000187:drug effects; D017277:Drug Approval; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced* / Q000276:immunology; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D013601:T-Lymphocytes / Q000187:drug effects
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D000069442:Natalizumab